Document Detail


Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis.
MedLine Citation:
PMID:  23037768     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective: Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus (HCV)-related compensated cirrhosis is still unclear. Methods: In study 1, in 157 consecutive patients with HCV-related compensated cirrhosis, treatment efficacy with interferon plus ribavirin therapy was evaluated for 48 weeks of HCV genotype 1b (HCV-1b) or 24 weeks of HCV-2a/2b. In study 2, in 185 consecutive patients with HCV-related compensated cirrhosis, who showed no sustained virological response following the first course of interferon monotherapy, hepatocarcinogenesis rates were evaluated according to the additional treatment, and they were classified into three groups: no treatment, interferon monotherapy, and ribavirin combination therapy. Results: In study 1, in HCV-1b, rates of sustained virological response and sustained biochemical response were 21 and 56%, respectively. In HCV-2a/2b, rates of sustained virological response and sustained biochemical response were 70 and 78%, respectively. In HCV-1b, sustained biochemical response rates were significantly higher than those of sustained virological response. In study 2, the hepatocarcinogenesis rates in ribavirin combination therapy were significantly lower than those in interferon monotherapy and no treatment, respectively. Conclusion: Ribavirin combination therapy for HCV-related compensated cirrhosis reduces the risk of hepatocarcinogenesis in comparison with interferon monotherapy, and higher rates of sustained biochemical response might be associated with lower hepatocarcinogenesis rates.
Authors:
Norio Akuta; Fumitaka Suzuki; Yuya Seko; Yusuke Kawamura; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Related Documents :
22162758 - Frequency of circulating regulatory t cells increases during chronic hiv infection and ...
1889308 - Inhibitory effect of tachyplesin i on the proliferation of human immunodeficiency virus...
21575628 - Selective cyclooxygenase inhibition improves hepatic encephalopathy in fulminant hepati...
22156858 - Differential clinical and virologic impact of hepatitis b virus genotypes b and c on hi...
8373998 - Hiv in the oral cavity: virus, viral inhibitory activity, and antiviral antibodies: a r...
12234138 - 5' dinucleotide repeat polymorphism of nramp1 and susceptibility to tuberculosis among ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-04
Journal Detail:
Title:  Intervirology     Volume:  -     ISSN:  1423-0100     ISO Abbreviation:  Intervirology     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364265     Medline TA:  Intervirology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human...
Next Document:  Inversion of axial chirality in coordinated bis-?-diketonato ligands.